Ortopedisk Klinikk, Ahus, 1478, Nordbyhagen, Norway.
Departement of Health Economics and Health Management, University of Oslo, Postboks1089, 0318, Oslo, Norway.
Knee Surg Sports Traumatol Arthrosc. 2018 Apr;26(4):1053-1058. doi: 10.1007/s00167-017-4632-5. Epub 2017 Jul 14.
The main purpose of the study is to put focus on the costs related to treating posterior cruciate ligament (PCL) injuries and the possible implications of chosen treatment strategy to the respective institutions and society.
Costs of treating PCL injuries nonoperatively and for both single-bundle (SB) and double-bundle (DB) reconstruction were estimated. These costs were translated into equivalent quality-adjusted life years (QALY) given a threshold value of Euro (€) 70,000 per QALY. Expected gain in knee osteoarthritis outcome score (KOOS) quality of life (QoL) following surgery based on KOOS data from 112 patients was used as a basis for calculating the cost efficiency ratio.
The average calculated cost of nonoperative treatment was €3382. Incremental cost for SB PCLR was €8585 (154%) and another increment of €5220 (61%) for DB PCLR using numbers from a European hospital. This is equivalent to increments of 0.074 (SB) and another 0.075 (DB) QALYs given the €70,000 threshold. For DB to be as cost efficient as SB reconstruction, the incremental gain in KOOS QoL has to be at the same level as for SB reconstruction compared to nonoperative treatment.
Though surgical reconstruction adds a substantial cost to nonoperative treatment alone, it can be considered cost-effective. Double-bundle reconstruction is less cost efficient than SB reconstruction, but should probably still be considered the treatment of choice for certain patient categories. Randomized controlled trials looking at outcome following nonoperative, SB and DB PCL reconstruction are needed. The clinical relevance of this is that surgical reconstruction of PCL injuries is a cost-efficient treatment alternative in patients with an isolated PCL injury. This finding should be taken into consideration when deciding on how to treat these injuries.
III.
本研究的主要目的是关注治疗后交叉韧带(PCL)损伤的相关成本,以及所选治疗策略对各机构和社会的可能影响。
估计了非手术治疗 PCL 损伤以及单束(SB)和双束(DB)重建的成本。这些成本被转化为等效的质量调整生命年(QALY),假设 QALY 的阈值为 70,000 欧元。根据 112 名患者的 KOOS 数据,基于手术治疗后膝关节骨关节炎结局评分(KOOS)生活质量(QoL)的预期改善,计算了成本效益比。
非手术治疗的平均计算成本为 3382 欧元。SB PCLR 的增量成本为 8585 欧元(154%),DB PCLR 的增量成本为 5220 欧元(61%),这些数字来自一家欧洲医院。这相当于在 70,000 欧元的阈值下,SB 的增量为 0.074,DB 的增量为 0.075 QALY。为了使 DB 重建与 SB 重建一样具有成本效益,DB 重建在 KOOS QoL 方面的增量增益必须与 SB 重建相比,与非手术治疗相当。
尽管手术重建比单纯非手术治疗增加了大量成本,但仍可被认为是具有成本效益的。DB 重建不如 SB 重建具有成本效益,但对于某些患者群体,它可能仍然是首选治疗方法。需要进行非手术、SB 和 DB PCL 重建后结局的随机对照试验。这一发现的临床意义在于,在决定如何治疗这些损伤时,PCL 损伤的手术重建是一种具有成本效益的治疗选择。
III。